Boston Scientific (NYSE: BSX) EVP awarded RSUs and stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Boston Scientific executive Padraig Andrew O'Connor, EVP Global Operations, reported several equity compensation transactions dated February 12, 2026. He exercised 1,058 restricted stock units into common shares and had 457 shares withheld at $74.12 per share to cover tax obligations, leaving 4,486 common shares directly owned.

He now directly holds 2,116 restricted stock units from earlier awards. On the same date, he received a new grant of 5,059 restricted stock units and 11,939 stock options. The RSUs and options vest in four equal annual installments beginning on February 12, 2027, with each unit or option tied to one share of common stock.

Insider Trade Summary

1,058 shares exercised/converted

Mixed 5 txns

Insider O'Connor Padraig Andrew

Role EVP, Global Operations

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,058	$0.00	--
Grant/Award	Restricted Stock Units	5,059	$0.00	--
Grant/Award	Stock Option (Right to Buy)	11,939	$0.00	--
Exercise	Common Stock	1,058	$0.00	--
Tax Withholding	Common Stock	457	$74.12	$34K

Holdings After Transaction: Restricted Stock Units — 2,116 shares (Direct); Stock Option (Right to Buy) — 11,939 shares (Direct); Common Stock — 4,943 shares (Direct)

Footnotes (1)

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

02/17/2026 - 07:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor Padraig Andrew

(Last)

(First)

(Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH

01752-1234

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Global Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/12/2026		M		1,058	A	$0.0000⁽¹⁾	4,943	D
Common Stock	02/12/2026		F		457	D	$74.12	4,486	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/12/2026		M			1,058	⁽²⁾	02/12/2028⁽²⁾	Common Stock	1,058	$0.0000	2,116	D
Restricted Stock Units	⁽¹⁾	02/12/2026		A		5,059		⁽³⁾	02/12/2030⁽³⁾	Common Stock	5,059	$0.0000	5,059	D
Stock Option (Right to Buy)	$74.12	02/12/2026		A		11,939		⁽⁴⁾	02/12/2036	Common Stock	11,939	$0.0000	11,939	D

Explanation of Responses:

1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

4. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BSX EVP Padraig O'Connor report?

Padraig O'Connor reported equity compensation activity, not open-market trades. He exercised 1,058 restricted stock units into common stock, had 457 shares withheld for taxes, and received new grants of 5,059 restricted stock units and 11,939 stock options, all dated February 12, 2026.

How many Boston Scientific shares does Padraig O'Connor own after these transactions?

After the transactions, O'Connor directly owns 4,486 common shares. This follows exercising 1,058 restricted stock units into common stock and a 457-share tax withholding. He also directly holds 2,116 restricted stock units plus newly granted awards that vest over time.

What restricted stock unit grants did BSX award to Padraig O'Connor?

Boston Scientific granted 5,059 new restricted stock units to O'Connor. Each unit represents a commitment to issue one share of common stock. These RSUs will be settled in four equal annual installments starting February 12, 2027, subject to the award’s vesting conditions.

What stock options did Boston Scientific grant to its EVP of Global Operations?

O'Connor received 11,939 stock options labeled as a right to buy shares. The options were granted on February 12, 2026 and vest in four equal annual installments beginning February 12, 2027, aligning with the company’s long-term equity incentive structure.

Was there an open-market sale of BSX shares in this Form 4?

The only disposition reported was a 457-share tax-withholding transaction. Shares were withheld at $74.12 per share to satisfy tax liability related to an equity award, rather than being sold in an open-market transaction initiated for investment purposes.

How do the vesting schedules work for O'Connor's BSX equity awards?

O'Connor’s RSU and option awards vest in four equal annual installments. Common stock from earlier RSUs begins issuing February 12, 2025, while the 5,059 RSUs and 11,939 options granted in 2026 start vesting on February 12, 2027, spreading value over several years.